Skip to main content


Abstract Nanotechnology produces a wide range of medicinal compounds, including nanoparticulate silver, which are increasingly introduced in
various forms for consumer use. As with all medicinal compounds. potential drug interactions are an important consideration for ingested silver
nanoparticles. Nanoparticulate silver-drug interactions may be mediated through induced oxidative stress in liver tissue where the majority of
systemically bioavailable silver nanoparticles is found. To investigate whether an orally ingested commercially available colloidal silver nanoproduct
produces pharmacokinetic interference on select cytochrome P450 enzymes, a prospective. single-blind, controlled in vivo human study using
simultaneous administration of standardized probes for P450 enzyme classes CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 was conducted.
Oral ingestion of a commercial colloidal silver nanoproduct produces detectable silver in human serum after 14 days of dosing. This silver, however,
elicits no demonstrable clinically significant changes in metabolic. hematologic, urinary, physical findings or cytochrome P450 enzyme inhibition or
induction activity. Given their increasingly broad, diverse human exposures, future characterization of human cytochrome P450 enzyme activity for
other systemically bioavailable nanotechnology products are warranted.

Study conducted using American Biotech Labs® 10ppm and 32ppm nano silver solutions.
KEYWORDS: Clinical study; in vivo; nanoparticles; pharmacokinetics; toxicology

PMID: 25137296 [PubMed – as supplied by publisher] IH » SN

LinkOut – more resources


PubMed Commons PubMed Commons home

CJ 0 comments
How to join PubMed Commons

“You are here: NCBI = Literature = PubMed


Leave a Reply